| Previous close | 123.20 |
| Open | 123.20 |
| Bid | 115.90 |
| Ask | 124.00 |
| Strike | 400.00 |
| Expiry date | 2025-01-17 |
| Day's range | 123.20 - 123.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 116 |
Investor's Business DailyIs Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug?
The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now?
ZacksWill Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GlobeNewswireBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
Designation is based on data from the clinical development program which demonstrated clinical proof of conceptFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 developmentFDA Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and which have potential to show substan
